Can a blood vessel drug beat aspirin at preventing heart attacks in diabetes?
NCT ID NCT07719894
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This trial compares two blood-thinning drugs—aspirin and cilostazol—to see which one better prevents major heart and blood vessel events in people with type 2 diabetes who are already at high risk. About 1,200 participants will be randomly assigned to take one of the two medications daily. The study tracks heart attacks, strokes, hospitalizations, and related deaths over time to determine which drug offers stronger protection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cilostazol or aspirin
- What this could lead to
- If cilostazol proves more effective than aspirin, it could offer a better option for preventing heart attacks and strokes in people with type 2 diabetes.
- What could go wrong
- This is a phase 4 trial, so both drugs are already approved, but cilostazol may cause side effects like headache or palpitations, and it is unclear if it will outperform aspirin.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATHEROSCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Seoul National University Bundang Hospital
RECRUITINGSeongnam-si, Gyeonggi-do, 13620, South Korea
Contact Phone: •••-•••-••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Student pharmacists may hold the key to better diabetes control in older asian adults
- New Dual-Action drug aims to tackle fatty liver where semaglutide falls short
- Can a 12-Week exercise program boost brain and body health in older adults with diabetes?
- Diabetes drugs may shield against severe pneumonia outcomes
- Could a green tea compound prevent second heart attacks?
- Saliva test could spot hidden links between diabetes and gum disease